Psychiatric adverse events in three phase III trials of eslicarbazepine acetate for focal seizures

OBJECTIVE: Eslicarbazepine acetate (ESL) is a once‐daily (QD), oral anti‐seizure medication for the treatment of focal (partial‐onset) seizures. Here, we evaluate risk factors for the development of psychiatric treatment‐emergent adverse events (TEAEs) in clinical trials of adjunctive ESL in adults...

Descripción completa

Detalles Bibliográficos
Autores principales: Altalib, Hamada, Grinnell, Todd, Cantu, David, Ikedo, Fábio, Vieira, Mariana, Zhang, Yi, Blum, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9712463/
https://www.ncbi.nlm.nih.gov/pubmed/35908275
http://dx.doi.org/10.1002/epi4.12635

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9712463/
https://www.ncbi.nlm.nih.gov/pubmed/35908275
http://dx.doi.org/10.1002/epi4.12635

Ejemplares similares